Inactive Instrument

Other languages Circadian Technologies Limited Australian S.E.

Equities

End-of-day quote Australian S.E. Other stock markets
- ^AUD	-

04-03	Opthea Limited Announces Board Changes	CI
02-29	Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	MT

Opthea Limited Announces Board Changes	04-03
Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	02-29
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28
Opthea Appoints Chief Medical Advisor; Shares Decline 4%	02-20
Opthea Appoints Arshad M. Khanani as Chief Medical Advisor	02-19
Opthea Concludes Enrollment in Inaugural Wet AMD Drug Trial	02-15
Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept	02-14
Opthea Makes Management Appointments As Part of Next Stage Drug Trial; Shares Up 13%	02-02
Opthea to Receive Remaining Committed Funds, Additional Financing for Sozinibercept Trials; Shares Up Pre-Bell	12-27
Traders Look Ahead to Flat Day After Post-Christmas Rally	12-27
Top Premarket Gainers	12-27
Opthea Secures $85 Million for Advancing Clinical Trials, Pre-Commercialization Activities	12-27
Opthea Receives AU$9 Million Tax Rebate for Fiscal Year 2023	12-20
Opthea Limited Announces Transition of Megan Baldwin to Founder and Chief Innovation Officer, Effective October 27, 2023	27/10/23
Opthea Limited Announces Executive Changes	27/10/23
Opthea Completes Retail Entitlement Offer; Shares Fall 3%	21/09/23
Opthea's Options Suspended from Quotation on ASX; Shares Rise 3%	15/09/23
Opthea Opens AU$16 Million Retail Entitlement Offer	31/08/23
Opthea Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23
Top Midday Decliners	28/08/23

No results for this search